drugset / Trial / NCT00601003
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether nifurtimox in combination with cyclophosphamide and topotecan are effective in the treatment of relapsed or refractory neuroblastoma and medulloblastoma.
Timeline
- Start
- 2008-01-14
- Primary completion
- 2020-04-28
- Completion
- 2022-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nifurtimox | Small molecule | 30 mg/kg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Intravenous |
| Background | Topotecan | Small molecule | 0.75 mg/m2 | Intravenous |